From: Robert J. Bradbury (bradbury@aeiveos.com)
Date: Tue Mar 19 2002 - 08:29:52 MST
Damien, is there any discussion in the book of the switch
that took place in the American strategy? Before Celera
was on the scene, the American strategy was similar to the
European strategy on the Yeast Genome Project -- many labs
taking a chunk of a chromosome and sequencing it. After
Celera was started it switched to more of an industrial mode.
They decided to dump a lot of money into scaling up just a
few labs (MIT, Washington University, the DOE Joint Genome
Center, and perhaps a couple of more). These are the labs
that ended up with rows and rows of capillary sequencers,
These were typically Molecular Dynamics machines because Celera
had a virtual lock on the production of the Applied Biosystems
machines.
In the end, much of the U.S. sequence came out of these labs
and not the couple of dozen centers that the project started
with.
Interestingly enough, there is such a lack of clarity with
respect to what to do next, the DOE is soliciting public
comments for the genomes it should be sequencing (they
have to be related to its mission however).
Robert
This archive was generated by hypermail 2.1.5 : Sat Nov 02 2002 - 09:13:01 MST